Tiffany Marsh

Tiffany Marsh currently serves as Vice President and Group Account Director at Heartbeat, where responsibilities include managing the account for OCREVUS (ocrelizumab) for multiple sclerosis since September 2017. Prior experience includes roles as Group Account Supervisor at FCB Health, and at Harrison and Star, focusing on Halaven (eribulin mesylate) for Eisai. Tiffany also held positions at Draftfcb Healthcare, where work centered on YERVOY (ipilimumab) for Bristol-Myers Squibb, and AgencyRx with Gleevec for Novartis Oncology. Earlier career stages featured roles as Event/Sales Manager at The Learning Annex and Development Associate at The Family Center. Educational qualifications include a Bachelor of Arts in Social Relations from Michigan State University and an MBA in Marketing from Long Island University.